Ruconest: a new option for the treatment of angioedema

Ruconest (conestat alfa) is a C1-esterase inhibitor analogue and is licensed for the treatment of acute attacks of hereditary angioedema type I or II.

Conestat alfa is produced from transgenic rabbits rather than being derived from human plasma
Conestat alfa is produced from transgenic rabbits rather than being derived from human plasma


Conestat alfa is a recombinant human complement component 1 (C1) esterase inhibitor obtained from rabbits.


In 2 double-blind studies, 70 patients with hereditary angioedema due to C1-esterase inhibitor  deficiency were randomised to receive conestat alfa 100 units/kg, 50 units/kg or placebo at the onset of an attack. In the pooled analysis, median time to beginning of symptom relief was significantly reduced in both treatment arms compared with placebo (66 minutes and 122 minutes vs 495 minutes, p<0.001 and p=0.013, respectively). Additionally, the median time to minimal symptoms was also significantly shorter in those receiving either 100 units/kg or 50 units/kg of conestat alfa compared with placebo (266 minutes and 247 minutes vs 1210 minutes, p<0.001 and p=0.001, respectively).

View Ruconest drug record

Further information: Swedish Orphan Biovitrum Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases